Scientific Poster Presentations

Novel Potent and Selective First-In-Class ERAP2 Inhibitors Modulate the Cancer Immnuopeptidome

Development of First-In-Class ERAP2 Inhibitors to Modulate the Cancer Immunopeptidome

Potential First-In-Class Inhibitors of ERAP1, Generating Cancer Antigens as Novel Targets for MHCI-Directed Therapies

Potential First-In-Class Inhibitors of ERAP1, Generating Cancer Antigens As Novel Targets For MHCI-Directed Therapies.

First-on-class Inhibitors of ERAP1 Have The Potential To Be A Transformative Immunotherapy In Oncology.

First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition.

GRWD5769: A first-in-class Inhibitor of ERAP1, Generating Novel Cancer Antigens to Drive De Novo Anti-Tumor T Cell Responses.

First-in-Class Inhibitors of ERAP1 Alter the Immunopeptidome of Cancer, Driving a Differentiated T Cell Response Leading to Tumor Growth Inhibition. Poster exhibited at SITC 10-14 Nov, 2021.

First-in-class inhibitors of ERAP1 modify the tumor-specific surfaceome, driving a differentiated T cell response and tumor growth inhibition. Poster exhibited at the SITC Surfaceome Workshop 2021.

First-in-class inhibitors of ERAP1 have the potential to be a transformative immunotherapy in oncology. Poster exhibited at AACR 2021 (9-14 Apr, 2021).

Immunopeptidome changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition. Poster exhibited at SITC 2020 (11-14 Nov, 2020).

Potent oral ERAP1 inhibitors modify the immunopeptidome in vivo and are novel immunotherapy agents. Poster exhibited at AACR 2020 (24-29 Apr, 2020).

Potent ERAP1 inhibitors modify the immunopeptidome and generate novel neoantigens. Poster exhibited at SITC 2019 (7-10 Nov, 2019).